$BIOLQ
BIOLASE, INC

2014 Q4 Form 10-K Financial Statement

#000156459016014571 Filed on March 11, 2016

View on sec.gov

Income Statement

Concept 2014 Q4 2014 2013 Q4
Revenue $13.24M $47.66M $15.24M
YoY Change -13.12% -15.55% -20.13%
Cost Of Revenue $8.230M $29.48M $9.030M
YoY Change -8.86% -15.52% -11.38%
Gross Profit $5.010M $18.17M $6.220M
YoY Change -19.45% -15.6% -30.03%
Gross Profit Margin 37.84% 38.13% 40.81%
Selling, General & Admin $7.480M $31.23M $7.200M
YoY Change 3.89% 11.3% 7.95%
% of Gross Profit 149.3% 171.85% 115.76%
Research & Development $1.350M $4.577M $1.040M
YoY Change 29.81% 13.6% 0.97%
% of Gross Profit 26.95% 25.19% 16.72%
Depreciation & Amortization $170.0K $696.0K $160.0K
YoY Change 6.25% 15.81% 14.29%
% of Gross Profit 3.39% 3.83% 2.57%
Operating Expenses $8.830M $36.11M $8.240M
YoY Change 7.16% 11.03% 7.01%
Operating Profit -$3.820M -$17.94M -$2.020M
YoY Change 89.11% 63.16% -269.75%
Interest Expense -$260.0K -$458.0K -$190.0K
YoY Change 36.84% -23.67% 35.71%
% of Operating Profit
Other Income/Expense, Net -$873.0K
YoY Change 34.31%
Pretax Income -$4.070M -$18.81M -$2.220M
YoY Change 83.33% 61.55% -309.43%
Income Tax $30.00K $112.0K $20.00K
% Of Pretax Income
Net Earnings -$4.110M -$18.93M -$2.230M
YoY Change 84.3% 64.83% -314.42%
Net Earnings / Revenue -31.04% -39.71% -14.63%
Basic Earnings Per Share -$0.45
Diluted Earnings Per Share -$392.2K -$0.45 -$329.4K
COMMON SHARES
Basic Shares Outstanding 42.23M
Diluted Shares Outstanding 42.23M

Balance Sheet

Concept 2014 Q4 2014 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.56M $31.56M $1.440M
YoY Change 2091.67% 2091.67% -43.31%
Cash & Equivalents $31.56M $31.56M $1.440M
Short-Term Investments
Other Short-Term Assets $1.730M $1.730M $1.910M
YoY Change -9.42% -9.42% 23.23%
Inventory $12.51M $12.51M $11.38M
Prepaid Expenses
Receivables $9.004M $8.890M $11.13M
Other Receivables $29.00K $110.0K $85.00K
Total Short-Term Assets $54.80M $54.80M $25.85M
YoY Change 111.95% 111.99% -3.95%
LONG-TERM ASSETS
Property, Plant & Equipment $1.295M $1.300M $1.826M
YoY Change -29.08% -28.96% 21.01%
Goodwill $2.926M $2.926M
YoY Change 0.0% 0.0%
Intangibles $183.0K
YoY Change -39.0%
Long-Term Investments
YoY Change
Other Assets $270.0K $270.0K $249.0K
YoY Change 8.43% 8.0% -18.36%
Total Long-Term Assets $4.605M $4.600M $5.184M
YoY Change -11.17% -11.37% 2.53%
TOTAL ASSETS
Total Short-Term Assets $54.80M $54.80M $25.85M
Total Long-Term Assets $4.605M $4.600M $5.184M
Total Assets $59.40M $59.40M $31.04M
YoY Change 91.39% 91.37% -2.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.360M $8.360M $8.560M
YoY Change -2.34% -2.34% 11.71%
Accrued Expenses $4.870M $4.870M $4.997M
YoY Change -2.54% 12.47% -20.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $4.630M
YoY Change -100.0% -100.0% 182.32%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.15M $16.15M $21.94M
YoY Change -26.39% -26.39% 13.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $520.0K $520.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $520.0K $520.0K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.15M $16.15M $21.94M
Total Long-Term Liabilities $520.0K $520.0K $0.00
Total Liabilities $17.35M $17.35M $22.56M
YoY Change -23.08% -23.09% 11.78%
SHAREHOLDERS EQUITY
Retained Earnings -$123.8M
YoY Change 10.23%
Common Stock $185.2M $148.9M
YoY Change 24.4% 437852.94%
Preferred Stock
YoY Change
Treasury Stock (at cost) $16.40M
YoY Change 0.0%
Treasury Stock Shares $1.964M
Shareholders Equity $42.06M $42.06M $8.481M
YoY Change
Total Liabilities & Shareholders Equity $59.40M $59.40M $31.04M
YoY Change 91.38% 91.37% -2.92%

Cashflow Statement

Concept 2014 Q4 2014 2013 Q4
OPERATING ACTIVITIES
Net Income -$4.110M -$18.93M -$2.230M
YoY Change 84.3% 64.83% -314.42%
Depreciation, Depletion And Amortization $170.0K $696.0K $160.0K
YoY Change 6.25% 15.81% 14.29%
Cash From Operating Activities -$5.930M -$16.20M -$2.210M
YoY Change 168.33% 74.27% -216.32%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $198.0K -$220.0K
YoY Change -95.45% -70.67% 144.44%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$10.00K -$200.0K -$220.0K
YoY Change -95.45% -70.8% 100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $34.80M $51.12M
YoY Change 882.85%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 34.82M 46.75M -310.0K
YoY Change -11332.26% 428.43% -43.64%
NET CHANGE
Cash From Operating Activities -5.930M -16.20M -2.210M
Cash From Investing Activities -10.00K -200.0K -220.0K
Cash From Financing Activities 34.82M 46.75M -310.0K
Net Change In Cash 28.88M 30.35M -2.740M
YoY Change -1154.01% -2776.37% -244.21%
FREE CASH FLOW
Cash From Operating Activities -$5.930M -$16.20M -$2.210M
Capital Expenditures -$10.00K $198.0K -$220.0K
Free Cash Flow -$5.920M -$16.40M -$1.990M
YoY Change 197.49% 64.46% -200.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
188622000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
200000
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
114000
CY2015Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
843000
CY2014Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
677000
CY2015Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
738000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9004000
CY2014Q4 us-gaap Inventory Net
InventoryNet
12508000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1726000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
54798000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1295000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
44000
CY2015Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
159000
CY2014Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
519000
CY2014Q4 us-gaap Goodwill
Goodwill
2926000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-17941000
CY2014 us-gaap Operating Expenses
OperatingExpenses
36113000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
185231000
CY2013 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-600000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-11482000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-650000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-164000
CY2013 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
46000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11436000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-640000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-873000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-18926000
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-283000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19209000
CY2014 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-458000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20100000
CY2014 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-415000
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
60000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-30000
CY2013 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-27000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-10996000
CY2013 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-50000
CY2013 us-gaap Operating Expenses
OperatingExpenses
32526000
CY2013 biol Excise Tax
ExciseTax
438000
CY2015 biol Litigation Expense Recovered
LitigationExpenseRecovered
731000
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
74000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
601000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18814000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11646000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
112000
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42232000
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32768000
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42232000
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32768000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
11794000
CY2012Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1964000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
709000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1609000
CY2013 biol Adjustments To Additional Paid In Capital Non Employee Equity Instruments
AdjustmentsToAdditionalPaidInCapitalNonEmployeeEquityInstruments
106000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
250000
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5169000
CY2013 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
280000
CY2014 us-gaap Treasury Stock Shares Retired
TreasuryStockSharesRetired
1964000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
123000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
51118000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3350000
CY2015 biol Common Stock Issuance Cost
CommonStockIssuanceCost
3000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
880000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
696000
CY2015 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-6000
CY2014 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-9000
CY2015 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
86000
CY2014 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1295000
CY2013 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
291000
CY2015 us-gaap Inventory Write Down
InventoryWriteDown
647000
CY2014 us-gaap Inventory Write Down
InventoryWriteDown
585000
CY2013 us-gaap Inventory Write Down
InventoryWriteDown
1132000
CY2015 biol Provision For Sales Returns Allowance
ProvisionForSalesReturnsAllowance
100000
CY2014 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
200000
CY2013 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
179000
CY2014 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
128000
CY2013 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
197000
CY2015 biol Share Based Compensation Net Of Credit
ShareBasedCompensationNetOfCredit
3350000
CY2014 biol Share Based Compensation Net Of Credit
ShareBasedCompensationNetOfCredit
1233000
CY2013 biol Share Based Compensation Net Of Credit
ShareBasedCompensationNetOfCredit
1609000
CY2013 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
106000
CY2014 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-123000
CY2013 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-250000
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
61000
CY2015 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
74000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
200000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
52000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-826000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-264000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
705000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-56000
CY2015 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-27000
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1715000
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1436000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
65000
CY2015 biol Increase Decrease In Accrued Legal Settlement
IncreaseDecreaseInAccruedLegalSettlement
1664000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
803000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-971000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
236000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17772000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16201000
CY2014 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
16875000
CY2014 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
45000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1778000
CY2015 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
107000
CY2013 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
35100000
CY2014 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
21508000
CY2013 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
32104000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-197000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-685000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
21000
CY2014 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-174000
CY2013 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-297000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
451000
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-999000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9296000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
675000
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6039000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
44000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1803000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
198000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
CY2013 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10000
CY2013 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
57000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51118000
CY2015 biol Deposit On Capital Lease
DepositOnCapitalLease
42000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-105000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-206000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-19861000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1440000
CY2015 us-gaap Interest Paid
InterestPaid
4000
CY2015 biol Interest Received
InterestReceived
79000
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.006
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13606000
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers&#8217; financial condition and maintains relationships with the Company&#8217;s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has have required certain distributors to make prepayments for significant purchases of products. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s revenue is denominated in U.S.&#160;dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company&#8217;s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the years ended December 31, 2015, 2014, and 2013 the Company did not enter into any hedging contracts. Future fluctuations in the value of the U.S.&#160;dollar may affect the price competitiveness of the Company&#8217;s products outside the U.S. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding balances on the Company&#8217;s lines of credit expose it to variable interest rate risks associated with fluctuations in the daily prime rate and the London Interbank Offered Rate (&#8220;LIBOR&#8221;) rate. Under the Company&#8217;s policies in place for the year ended December 31, 2015, it does not use interest rate derivative instruments to manage exposure to interest rate changes. Increases in the daily prime rate or LIBOR rate would increase the costs of borrowing and accordingly, the interest expense the Company must pay. However, as of December 31, 2015, the Company did not have a line of credit facility.</p></div>
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4800000
CY2014Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11500000
CY2014Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34800000
CY2015Q4 biol Working Capital
WorkingCapital
19700000
CY2015Q4 biol Cash And Cash Equivalents And Restricted Cash
CashAndCashEquivalentsAndRestrictedCash
12000
CY2015 us-gaap Depreciation
Depreciation
817000
CY2014 us-gaap Depreciation
Depreciation
627000
CY2013 us-gaap Depreciation
Depreciation
484000
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2015 us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
210000
CY2014 us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
110000
CY2015Q4 us-gaap Extended Product Warranty Accrual
ExtendedProductWarrantyAccrual
1400000
CY2014Q4 us-gaap Extended Product Warranty Accrual
ExtendedProductWarrantyAccrual
1500000
CY2013Q4 biol Percentage Of Fair Value Of Exchange To Recognize Revenue
PercentageOfFairValueOfExchangeToRecognizeRevenue
0.25
CY2014Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1449000
CY2013Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1096000
CY2012Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1699000
CY2015 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1715000
CY2014 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1214000
CY2013 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
475000
CY2015 us-gaap Product Warranty Expense
ProductWarrantyExpense
976000
CY2014 us-gaap Product Warranty Expense
ProductWarrantyExpense
861000
CY2013 us-gaap Product Warranty Expense
ProductWarrantyExpense
1078000
CY2015Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
2188000
CY2015Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1345000
CY2014Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
930000
CY2013Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1096000
CY2015 us-gaap Advertising Expense
AdvertisingExpense
929000
CY2014 us-gaap Advertising Expense
AdvertisingExpense
543000
CY2013 us-gaap Advertising Expense
AdvertisingExpense
1500000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3350000
CY2014Q4 us-gaap Deferred Revenue
DeferredRevenue
2494000
CY2015Q4 biol Deferred Royalties Noncurrent
DeferredRoyaltiesNoncurrent
142000
CY2015 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
119000
CY2015Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
445000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
681000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1233000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1609000
CY2015 biol Share Based Compensation Net Impact On Earning Per Share Diluted
ShareBasedCompensationNetImpactOnEarningPerShareDiluted
0.06
CY2014 biol Share Based Compensation Net Impact On Earning Per Share Diluted
ShareBasedCompensationNetImpactOnEarningPerShareDiluted
0.03
CY2013 biol Share Based Compensation Net Impact On Earning Per Share Diluted
ShareBasedCompensationNetImpactOnEarningPerShareDiluted
0.05
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4400000
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1400000
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y9M29D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y7M24D
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.90
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.94
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.84
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0164
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0166
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0104
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14587000
CY2015Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
8850000
CY2014Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
8887000
CY2015Q4 biol Royalty Revenues Receivable
RoyaltyRevenuesReceivable
61000
CY2014Q4 biol Royalty Revenues Receivable
RoyaltyRevenuesReceivable
88000
CY2015Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
37000
CY2014Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
29000
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1800000
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1700000
CY2015Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3627000
CY2014Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2857000
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1379000
CY2014Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1348000
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7560000
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8303000
CY2015Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2100000
CY2014Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2400000
CY2015Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
9883000
CY2014Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
6788000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6314000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5669000
CY2015Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
3569000
CY2014Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1119000
CY2015Q4 us-gaap Land
Land
158000
CY2014Q4 us-gaap Land
Land
176000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1905000
CY2014Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
139000
CY2015Q4 biol Capital Lease And Warranty Obligations Current
CapitalLeaseAndWarrantyObligationsCurrent
167000
CY2014Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
450000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
183000
CY2015Q4 us-gaap Extended Product Warranty Accrual Current
ExtendedProductWarrantyAccrualCurrent
1428000
CY2014Q4 us-gaap Extended Product Warranty Accrual Current
ExtendedProductWarrantyAccrualCurrent
1542000
CY2015Q4 biol Deferred Royalties Current
DeferredRoyaltiesCurrent
261000
CY2015Q4 us-gaap Deferred Revenue
DeferredRevenue
3297000
CY2015 us-gaap Litigation Settlement Amount
LitigationSettlementAmount
1400000
CY2015Q4 biol Legal Settlement At Present Value
LegalSettlementAtPresentValue
1200000
CY2015 biol Settlement Expense For Dismissal Of Patent Infringement Lawsuit Recovered
SettlementExpenseForDismissalOfPatentInfringementLawsuitRecovered
68000
CY2015 us-gaap Royalty Revenue
RoyaltyRevenue
119000
CY2015Q4 biol Deferred Royalties
DeferredRoyalties
261000
CY2015 biol Deferred Training Service Revenue Maximum Recognition Period
DeferredTrainingServiceRevenueMaximumRecognitionPeriod
P24M
CY2015 biol Deferred Training Service Revenue Minimum Recognition Period
DeferredTrainingServiceRevenueMinimumRecognitionPeriod
P9M
CY2014Q3 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
708000
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
63000
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
69000
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
117000
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
51000
CY2015Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2749000
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2686000
CY2015 biol Indefinite Lived Intangible Assets Useful Life
IndefiniteLivedIntangibleAssetsUsefulLife
Indefinite life
CY2015Q4 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2014Q4 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2014 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
457000
CY2013 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
599000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-138000
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
30000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
27000
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
31000
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
87000
CY2014 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
25000
CY2013 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-27000
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
117000
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
52000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-134000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
61000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
60000
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
72000
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-118000
CY2013 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
16000
CY2013 biol Current Federal Tax Expense Benefit Gross
CurrentFederalTaxExpenseBenefitGross
138000
CY2013 biol Income Tax Reconciliation Tax Credits Alternative Minimum Tax And Research And Development
IncomeTaxReconciliationTaxCreditsAlternativeMinimumTaxAndResearchAndDevelopment
107000
CY2013 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
245000
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.402
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.374
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.270
CY2013 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.009
CY2013 biol Effective Income Tax Rate Reconciliation Reduction Of Net Operating Loss
EffectiveIncomeTaxRateReconciliationReductionOfNetOperatingLoss
0.031
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.031
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.033
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.031
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.019
CY2015 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.001
CY2014 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.001
CY2015Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
104000
CY2014Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
202000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
2527000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
1871000
CY2015Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4072000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2911000
CY2015Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
9000
CY2014Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
8000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2471000
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.004
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.010
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.009
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.023
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.005
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.008
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2200000
CY2015Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
905000
CY2014Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
1225000
CY2015Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
345000
CY2014Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
280000
CY2015Q4 us-gaap Deferred Tax Assets Other Comprehensive Loss
DeferredTaxAssetsOtherComprehensiveLoss
320000
CY2014Q4 us-gaap Deferred Tax Assets Other Comprehensive Loss
DeferredTaxAssetsOtherComprehensiveLoss
222000
CY2015Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
136000
CY2014Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
136000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
38753000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33140000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
49650000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42203000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49514000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42069000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
136000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
134000
CY2015Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
813000
CY2014Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
752000
CY2015Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
61000
CY2014Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
59000
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
874000
CY2014Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
811000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
109500000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
71800000
CY2015 biol Unrecognized Tax Benefits That Would Impact Additional Paid In Capital
UnrecognizedTaxBenefitsThatWouldImpactAdditionalPaidInCapital
6900000
CY2014 biol Unrecognized Tax Benefits That Would Impact Additional Paid In Capital
UnrecognizedTaxBenefitsThatWouldImpactAdditionalPaidInCapital
6900000
CY2015Q4 biol Unrecognized Tax Benefits Impact Additional Paid In Capital If Realized
UnrecognizedTaxBenefitsImpactAdditionalPaidInCapitalIfRealized
2600000
CY2014Q4 biol Unrecognized Tax Benefits Impact Additional Paid In Capital If Realized
UnrecognizedTaxBenefitsImpactAdditionalPaidInCapitalIfRealized
2600000
CY2013Q4 biol Percentage Of Valuation Allowance Of State Deferred Tax Assets
PercentageOfValuationAllowanceOfStateDeferredTaxAssets
1.00
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
568000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
568000
CY2015Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0
CY2006Q1 biol Lease Facility Area
LeaseFacilityArea
57000
CY2015Q1 biol Period For Extended Lease
PeriodForExtendedLease
2020-04-30
CY2015Q1 biol Provisions For Tenant Improvement Allowance Maximum
ProvisionsForTenantImprovementAllowanceMaximum
398000
CY2015Q1 biol Capital Lease Agreement Lease Term
CapitalLeaseAgreementLeaseTerm
P30M
CY2015Q4 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.016
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
147000
CY2015Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
153000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
219000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3164000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1100000
CY2015Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
13400000
CY2015Q4 biol Litigation Settlement Amount Receivable Non Current
LitigationSettlementAmountReceivableNonCurrent
825000
CY2015Q4 biol Receivable For Legal Settlements On First Anniversary
ReceivableForLegalSettlementsOnFirstAnniversary
275000
CY2015Q4 biol Receivable For Legal Settlements On Second Anniversary
ReceivableForLegalSettlementsOnSecondAnniversary
275000
CY2015Q4 biol Receivable For Legal Settlements On Third Anniversary
ReceivableForLegalSettlementsOnThirdAnniversary
275000
CY2015Q4 biol Litigation Settlement Amount Receivable Current
LitigationSettlementAmountReceivableCurrent
550000
CY2015 us-gaap Loss Contingency Settlement Agreement Terms
LossContingencySettlementAgreementTerms
As part of the settlement, Fotona agreed to pay the Company a total of $1.4 million, with $550,000 payable within 10 days of March 24, 2015 and the remaining, $825,000 payable in three increments of $275,000 each to be paid no later than the first, second, and third anniversary of the effective date of the agreement.
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2013Q3 biol Maximum Stock Offering Price
MaximumStockOfferingPrice
5000000
CY2015 biol Dividend Declared
DividendDeclared
0
CY2014 us-gaap Dividends Payable Date Declared Day Month And Year
DividendsPayableDateDeclaredDayMonthAndYear
2014-03-05
CY2014 us-gaap Dividends Payable Date Of Record Day Month And Year
DividendsPayableDateOfRecordDayMonthAndYear
2014-03-14
CY2014 us-gaap Dividend Payable Date To Be Paid Day Month And Year
DividendPayableDateToBePaidDayMonthAndYear
2014-03-28
CY2014Q4 biol Dividends Paid Amount Per Share
DividendsPaidAmountPerShare
0.0050
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37422753
CY2014 us-gaap Dividends
Dividends
193032
CY2013Q1 biol Required Minimum Share Price Reached To Exercise Warrants
RequiredMinimumSharePriceReachedToExerciseWarrants
6.00
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3860000
CY2013 biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
711000
CY2013 biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Above Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtAboveFairMarketValue
978000
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
343000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
765000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4441000
CY2014 biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
240000
CY2014 biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Above Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtAboveFairMarketValue
369000
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
153000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1422000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3475000
CY2015 biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
1931000
CY2015 biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Above Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtAboveFairMarketValue
1340000
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
38000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2215000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4493000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2739000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1038000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.48
CY2013 biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
3.79
CY2013 biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period At Above Fair Market Value Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodAtAboveFairMarketValueWeightedAverageExercisePrice
3.72
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.07
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.23
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.51
CY2014 biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
2.23
CY2014 biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period At Above Fair Market Value Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodAtAboveFairMarketValueWeightedAverageExercisePrice
3.05
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.03
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.50
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.03
CY2015 biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
2.22
CY2015 biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period At Above Fair Market Value Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodAtAboveFairMarketValueWeightedAverageExercisePrice
2.46
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.15
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.64
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.72
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.96
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.82
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M2D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y5M16D
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
422
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
422
CY2015Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
4493000
CY2015Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.72
CY2015 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y7M2D
CY2015Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2739000
CY2015Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.96
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
52000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
108000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
860000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.54
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.61
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.82
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2268000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1208000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1544000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1826000

Files In Submission

Name View Source Status
0001564590-16-014571-index-headers.html Edgar Link pending
0001564590-16-014571-index.html Edgar Link pending
0001564590-16-014571.txt Edgar Link pending
0001564590-16-014571-xbrl.zip Edgar Link pending
biol-10k_20151231.htm Edgar Link pending
biol-20151231.xml Edgar Link completed
biol-20151231.xsd Edgar Link pending
biol-20151231_cal.xml Edgar Link unprocessable
biol-20151231_def.xml Edgar Link unprocessable
biol-20151231_lab.xml Edgar Link unprocessable
biol-20151231_pre.xml Edgar Link unprocessable
biol-ex211_7.htm Edgar Link pending
biol-ex231_598.htm Edgar Link pending
biol-ex311_810.htm Edgar Link pending
biol-ex312_811.htm Edgar Link pending
biol-ex321_809.htm Edgar Link pending
biol-ex322_808.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2016031120574637211056.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending